Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 1461 Pancreatic Neoplasms 832 Stomach Neoplasms 692 Carcinoma, Hepatocellular 647 Carcinoma, Non-Small-Cell Lung 540 Neoplasms 459 Breast Neoplasms 369 Ovarian Neoplasms 338 Neoplasm Metastasis 336 Colonic Neoplasms 331 Esophageal Neoplasms 297 Liver Neoplasms 265 Melanoma 255 Lung Neoplasms 245 Squamous Cell Carcinoma of Head and Neck 210 Cholangiocarcinoma 180 Carcinoma, Renal Cell 180 Prostatic Neoplasms 175 Head and Neck Neoplasms 172 Triple Negative Breast Neoplasms 162 Endometrial Neoplasms 160 Rectal Neoplasms 159 Uterine Cervical Neoplasms 155 Gastrointestinal Neoplasms 142 Urinary Bladder Neoplasms 139 Biliary Tract Neoplasms 135 Gastrointestinal Stromal Tumors 108 Sarcoma 104 Esophageal Squamous Cell Carcinoma 102 Small Cell Lung Carcinoma 95

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Anal Cancer Metastatic × Gastrointestinal × Clear all

NCT07280377 2026-05-19

GOBLET

Oncolytics Biotech

Phase 1/2 Active not recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡